Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN

NCT02101034 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02101034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02101034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Completed
Start date
June 17, 2014
Completion date
November 10, 2023
Enrollment
96 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell of head and neck